AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.35 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $8,088,000 | +72.4% | 753,037 | +53.3% | 0.86% | +119.5% |
| Q3 2021 | $4,691,000 | -23.5% | 491,159 | +84.8% | 0.39% | -27.7% |
| Q4 2020 | $6,136,000 | -65.1% | 265,753 | -78.6% | 0.54% | -68.4% |
| Q3 2020 | $17,559,000 | -28.5% | 1,243,550 | -23.6% | 1.72% | -25.3% |
| Q2 2020 | $24,559,000 | +31.7% | 1,628,550 | -19.3% | 2.31% | -0.9% |
| Q1 2020 | $18,643,000 | -31.6% | 2,017,624 | -28.0% | 2.33% | +3.7% |
| Q4 2019 | $27,275,000 | +16.1% | 2,800,320 | -4.4% | 2.25% | -38.1% |
| Q3 2019 | $23,501,000 | -25.0% | 2,930,320 | +16.7% | 3.63% | -15.3% |
| Q2 2019 | $31,329,000 | -7.4% | 2,510,320 | +0.9% | 4.29% | +38.8% |
| Q1 2019 | $33,838,000 | +44.3% | 2,488,078 | +1.6% | 3.09% | +16.9% |
| Q4 2018 | $23,452,000 | +8.5% | 2,447,994 | +36.9% | 2.64% | +6.5% |
| Q3 2018 | $21,617,000 | +16.4% | 1,787,994 | +50.4% | 2.48% | -3.1% |
| Q2 2018 | $18,573,000 | -33.1% | 1,189,056 | -35.6% | 2.56% | -39.2% |
| Q1 2018 | $27,759,000 | +75.4% | 1,845,704 | +67.8% | 4.22% | +127.0% |
| Q4 2017 | $15,829,000 | +149.9% | 1,100,000 | +161.9% | 1.86% | +105.4% |
| Q3 2017 | $6,334,000 | +57.2% | 420,000 | +5.0% | 0.90% | +32.2% |
| Q2 2017 | $4,028,000 | +13.0% | 400,000 | -20.0% | 0.68% | -1.9% |
| Q1 2017 | $3,565,000 | -1.7% | 500,000 | -31.5% | 0.70% | -24.1% |
| Q4 2016 | $3,628,000 | -45.8% | 730,000 | -19.3% | 0.92% | -15.8% |
| Q3 2016 | $6,697,000 | +22.1% | 905,000 | -10.0% | 1.09% | -23.5% |
| Q2 2016 | $5,487,000 | +116.4% | 1,005,000 | +235.0% | 1.42% | +159.6% |
| Q1 2016 | $2,535,000 | -41.5% | 300,000 | -3.2% | 0.55% | -0.7% |
| Q3 2015 | $4,337,000 | -31.9% | 310,000 | -31.1% | 0.55% | -11.4% |
| Q2 2015 | $6,368,000 | +30.1% | 450,000 | 0.0% | 0.62% | +22.4% |
| Q1 2015 | $4,896,000 | +7.0% | 450,000 | -18.2% | 0.51% | -34.6% |
| Q4 2014 | $4,576,000 | – | 550,000 | – | 0.78% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |